viewErgomed PLC

Expansion of Modus study 'great news for Ergomed Plc'

Ergomed Plc (LON:ERGO) has been cheered by news of progress in a medical study by one of its co-development partners, Modus Therapeutics.

The pharma services and drug development group drew its shareholders’ attention to an announcement by Modus relating to Sevuparin, a new drug to treat people suffering from Sickle Cell Disease.

Ergomed Chief business officer Andrew Mackie tells Proactive: ''It's great news for us. The Independent Data Safety Monitoring Board have had a look at the first 25 patients included in the study and they've concluded that it's safe to continue.''

''Also, because of the safety profile seen so far they've actually allowed us to open up the recruitment to young patients - this will enable us to increase the pace of recruitment in the study ... and ultimately when it gets to market it will be able to serve a wider population''.

Top line are results now expected in the first half of 2018 rather than in the first half of next year.

Quick facts: Ergomed PLC

Price: 1000 GBX

Market: AIM
Market Cap: £487.2 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Ergomed PLC named herein, including the promotion by the Company of Ergomed PLC in any Content on the Site, the Company receives from said...


Ergomed expanding via earnings-enhancing acquisitions

Andrew Mackie, chief business officer of Ergomed Plc (LON: ERGO), says the company is looking for more opportunities to expand via acquisition principally specialist service companies operating in the post-marketing arena. The pharma services specialist has just bought Haemostatix and its...

on 05/05/2016

2 min read